Zmęczenie w zespole Sjögrena: 3 strategie terapeutyczne (FESSONA)
Zmęczenie w zespole Sjögrena: randomizowane kontrolowane badanie połączonych niefarmakologicznych strategii terapeutycznych
Unexplained fatigue is a frequent (60-70%) chronic complaint in Sjögren's syndrome (SjS) with a clear unmet therapeutic need, despite the recommendation of adapted physical activity (APA) programs, which are effective and feasible, but only to some extent. Hence, other therapeutic approaches, such as Acupuncture (ACU) or transcutaneous vagal nerve stimulation (tVNS), have been evaluated during the past years, with varying degrees of success in alleviating fatigue.
FESSONA has been designed as a randomized controlled monocentric trial, aiming at comparing the effects of 3 different programs on fatigue in SjS: APA alone, APA+ACU and APA+tVNS. Relevant controls will be included as well (sham ACU and simulated tVNS).
Multiple fatigue and SjS-related features will be measured before (at inclusion) and after (week 12) the intervention, as well as at week 24 and 48, to evaluate the short- and long-term impact of each program. Tolerance and feasibility will also be evaluated.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Martin KILLIAN, MD
- Numer telefonu: +33 (33)477 82 91 79
- E-mail: martin.killian@chu-st-etienne.fr
Kopia zapasowa kontaktu do badania
- Nazwa: Florence RANCON, Chef de projet
- Numer telefonu: +33 (33)477829458
- E-mail: florence.rancon@chu-st-etienne.fr
Lokalizacje studiów
-
-
-
Saint-Etienne, Francja, 42055
- Rekrutacyjny
- Chu de Saint-Etienne
-
Pod-śledczy:
- David HUPIN, MD
-
Pod-śledczy:
- Hubert MAROTTE, MD PhD
-
Pod-śledczy:
- Baptiste GRAMONT, MD
-
Kontakt:
- Martin KILLIAN, MD
- Numer telefonu: +33 (33) 4 77 82 91 79
- E-mail: martin.killian@chu-st-etienne.fr
-
Kontakt:
- Florence RANCON, Chef de projet
- Numer telefonu: +33 (33) 4 77 82 94 58
- E-mail: florence.rancon@chu-st-etienne.fr
-
Pod-śledczy:
- Lucile GRANGE, MD
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Patient affiliated or entitled to a social security scheme.
- Age > 18 years.
- Patient informed and having signed the information form and consent to participate in the study.
- Patient with Sjögren's syndrome according to ACR/EULAR 2016 or AECG 2002 criteria, usually followed up every year or more frequently
- Fatigue present for ≥ 6 months, without obvious explanation and/or specific treatment to conduct (e.g., disease's flare, chronic infection), with a current FACIT-F score < 34
Exclusion Criteria:
- Pre-existing atrial fibrillation or severe cardiac conduction disorders,
- Recent stroke or myocardial infarction (<6 months),
- Left ventricular ejection fraction <40% or severe heart failure (New York Heart Association functional class III or IV)
- Recurrent episodes of vasovagal syncope, or history of vagotomy
- People with dermatological problems in the area where the stimulation electrodes are to be placed
- Current episode of venous or arterial thrombosis
- Pregnancy or breastfeeding
- Patient under protective measures (legal protection, curatorship, guardianship)
- Inability or refusal to understand and/or sign informed consent to participate in the study, or to perform follow-up examinations required under the study
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Inny
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: APA + Sham ACU + TVNS
|
Transcutaneous Vagus Nerve Stimulation (tVNS) will be performed using an ECO TENS 2 device with an ear clip put in the conque aurea of the left ear, which is innervated by the auricular branch of the vagus nerve. In the groups receiving simulated tVNS, stimulation will be delivered to the ear lobe, which is devoid of vagal innervation. Stimulation will be delivered at a frequency of 20 Hz and a pulse width of 200 ms, while the stimulation amplitude will be individually titrated to 1 mA below the level that will lead to a mild unpleasant feeling, according to the parameters defined by Stavrakis et al (2017, 2020). The APA (adapted physical activity ) program : 2 sessions of 90 min (with 60 min of aerobic exercise and 30 min of resistance exercises per session) per week, for 12 consecutive weeks Needles well be used in the non-acupoint area 2 centimeters away from the real acupoints. The needles will remain for 30 min. Subjects will receive sham acupuncture twice a week during the 12-week intervention. |
|
Eksperymentalny: Symulowane TVN APA + ACU +
|
The APA (adapted physical activity ) program : 2 sessions of 90 min (with 60 min of aerobic exercise and 30 min of resistance exercises per session) per week, for 12 consecutive weeks acupoints will be Baihui (GV20); Zhongwan (CV12), Guanyuan (CV4), bilateral Zusanli (ST36) bilateral Taichong (LV3). The needles will remain for 30 min. Subjects will receive acupuncture twice a week during the 12-week intervention. Simulated Transcutaneous Vagus Nerve Stimulation (sim_tVNS) will be performed using an ECO TENS 2 device with an ear clip put in the conque aurea of the left ear, which is innervated by the auricular branch of the vagus nerve. NSVt devices will be used in "simulated" mode. |
|
Pozorny komparator: APA + symulowane TVNS + Sham ACU
|
The APA (adapted physical activity ) program : 2 sessions of 90 min (with 60 min of aerobic exercise and 30 min of resistance exercises per session) per week, for 12 consecutive weeks Needles well be used in the non-acupoint area 2 centimeters away from the real acupoints. The needles will remain for 30 min. Subjects will receive sham acupuncture twice a week during the 12-week intervention. Simulated Transcutaneous Vagus Nerve Stimulation (sim_tVNS) will be performed using an ECO TENS 2 device with an ear clip put in the conque aurea of the left ear, which is innervated by the auricular branch of the vagus nerve. NSVt devices will be used in "simulated" mode. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in fatigue score assessed
Ramy czasowe: Between inclusion (week 0) and visit V1 at 12 weeks (± 1 week from the end of the 12-week program)
|
Change in fatigue score assessed using the FACIT-F questionnaire (Functional Assessment of Chronic Illness Therapy - Fatigue; ranging from 0 to 52, 0 meaning extreme fatigue and 52 the total absence of fatigue) |
Between inclusion (week 0) and visit V1 at 12 weeks (± 1 week from the end of the 12-week program)
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Odsetek (w %) przeprowadzonych 24 sesji APA (co najmniej 80 % proponowanych ćwiczeń) w różnych grupach
Ramy czasowe: Tydzień 48
|
Tydzień 48
|
|
|
FACIT-F score in the different groups
Ramy czasowe: between inclusion (Week 0) and week 48
|
FACIT-F score at 48 weeks, in the different groups |
between inclusion (Week 0) and week 48
|
|
Root Mean Square of the Successive Differences in heart rate or RMSSD (in milliseconds)
Ramy czasowe: at 12, 24 and 48 weeks,
|
Root Mean Square of the Successive Differences in heart rate or RMSSD (in milliseconds), measured from a nocturnal ECG recording by Holter ECG, in the different groups |
at 12, 24 and 48 weeks,
|
|
ClinESSDAI score
Ramy czasowe: at 12, 24 and 48 weeks,
|
ClinESSDAI score (clinical part of the EULAR Sjögren's Syndrome Disease Activity Index; assessed on 11 "domains" corresponding to the main clinical manifestations of the disease; ranging from 0 to 135, a score of 0 meaning the existence of a disease and a score of 135 a disease whose activity would be maximal) in the different groups |
at 12, 24 and 48 weeks,
|
|
ESSPRI questionnaire (EULAR Sjögren's Syndrome Patient Reported Index)
Ramy czasowe: at 12, 24 and 48 weeks
|
ESSPRI questionnaire (EULAR Sjögren's Syndrome Patient Reported Index); calculated as the mean of 3 self-measurement scales assessing fatigue, dryness and pain, each ranging from 0 to 10; 0 meaning the total absence of the symptom considered and 10 a symptom whose intensity would be at the maximum imaginable) in the different groups |
at 12, 24 and 48 weeks
|
|
HADS questionnaire (Hospital Anxiety and Depression Scale)
Ramy czasowe: at 12, 24 and 48 weeks
|
HADS questionnaire (Hospital Anxiety and Depression Scale) composed of an anxiety score and a depression score both ranging from 0 to 21, 0 meaning the absence of symptoms of this type, and 21 the presence of an anxiety and/or major depressive state) in the different groups |
at 12, 24 and 48 weeks
|
|
Self-measurement questionnaire SF-36 (Short Form Health Survey 36)
Ramy czasowe: between inclusion (Week 0) and week 48
|
Self-measurement questionnaire SF-36 (Short Form Health Survey 36); comprising 36 questions assessing 8 dimensions, namely physical functioning, role limitation due to physical problems, role limitation resulting from emotional problems, vitality (energy/fatigue), emotional well-being, social functioning, bodily pain, and perception of general and mental health; each dimension is represented by a score ranging from 0 to 100, with a low score signifying poor health perception in the dimension considered, and a high score signifying the opposite) |
between inclusion (Week 0) and week 48
|
|
EQ-5D-5L self-measurement questionnaire assessing 5 dimensions of health
Ramy czasowe: at 12, 24, and 48 weeks,
|
EQ-5D-5L self-measurement questionnaire assessing 5 dimensions of health (mobility, autonomy, daily activities, pain/discomfort and anxiety/depression) with 1 question per domain, with the possibility of choosing 5 degrees of severity each time (1 corresponding to no difficulty for the domain and 5 corresponding to the maximum degree of difficulty in the domain), the total of the 5 notes of the 5 domains giving a score ranging from 5 to 25, and this questionnaire is associated with a visual analogue scale (VAS) allowing the patient to rate his state of health of the day from 0 (the worst state of health imaginable) to 100 (the best state of health imaginable), in the different groups |
at 12, 24, and 48 weeks,
|
|
Schirmer test
Ramy czasowe: at 12, 24 and 48 weeks
|
the area of the graduated blotter that became wet after 5 min of placement on the lower eyelid of each eye, expressed in millimeters and as the average of the two eyes) at 12, 24 and 48 weeks, in the different groups |
at 12, 24 and 48 weeks
|
|
VO2max
Ramy czasowe: at 12, 24 and 48 weeks
|
VO2max (in ml/min/kg; after metabolic test) in the different groups |
at 12, 24 and 48 weeks
|
|
Handgrip test
Ramy czasowe: at 12, 24 and 48 weeks
|
Handgrip test (in kg; via a grip test on the dominant upper limb) in the different groups |
at 12, 24 and 48 weeks
|
|
Number of daily steps
Ramy czasowe: at 12, 24 and 48 weeks
|
Number of daily steps measured via a connected watch on average over the week preceding the assessments at 12, 24 and 48 weeks, in the different groups |
at 12, 24 and 48 weeks
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Główny śledczy: Martin KILLIAN, MD
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu mięśniowo-szkieletowego
- Choroby jamy ustnej
- Choroby Stomatognatyczne
- Artretyzm
- Choroby stawów
- Choroby reumatyczne
- Choroby tkanki łącznej
- Choroby Autoimmunologiczne
- Choroby układu odpornościowego
- Choroby oczu
- Zapalenie stawów, reumatoidalne
- Kserostomia
- Choroby gruczołów ślinowych
- Zespoły suchego oka
- Choroby aparatu łzowego
- Stany patologiczne, oznaki i objawy
- Choroby skóry i tkanki łącznej
- Objawy i symptomy
- Zmęczenie
- Zespół Sjogrena
- Lecznictwo
- Terapie uzupełniające
- Hydrolazy
- Enzymy
- Enzymy i koenzymy
- Hydrolazy peptydowe
- Metaloproteaza
- Egzopeptydazy
- Metaloeksopeptydazy
- Aminopeptydazy
- Terapia akupunktury
- Glutamyl aminopeptydaza
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- 24CH125
- ANSM (Inny identyfikator: 2024-A02116-41)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .